The Global Health Body Sounds Concern Over Critical Lack of Weight-Loss Injections
Less than 10% of individuals who could benefit from GLP-1 drugs including Wegovy are able to get them, states the global health agency as it releases its first recommendations on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable access to this class of drugs.
According to projections, more than two billion could be obese by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a long-term condition that can be addressed with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant barriers to widespread access to the injections that can help people shift significant weight, notes the agency.
Weight-Loss Drug Supply Crisis
Even in the present best projected scenario, the manufacturing of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice urges governments and firms to widen access, by strategies including patent sharing.
The intellectual property rights on a key compound – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Drugs Work
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and increase feelings of fullness so individuals reduce food intake.
People typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Evidence points to patients may regain a significant portion after a year of discontinuing the drug, because their normal food cravings return.
Being overweight or obese increases your chance for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts individuals in every country and was associated with millions of deaths worldwide in 2024, according to the health agency.
